Radioimmunotherapy (RIT) involves a small amount of radioactive material (radionuclide) — that is combined with a molecule engineered in a laboratory (monoclonal antibody). This monoclonal antibody-radionuclide compound is called a radiopharmaceutical. Monoclonal antibodies are able to recognize and bind to specific features of cells, such as antigens and cell receptors. When injected into the patient’s bloodstream, the radiopharmaceutical attaches to cancer cells, delivering a high dose of radiation to be delivered to the tumor.
Home Overview of Immunotherapy in Cancer Treatment What is Radioimmunotherapy